US2019262406A1PendingUtilityA1

Methods and compositions for treatment of bone defects with placental cell populations

62
Assignee: CELULARITY INCPriority: Oct 23, 2006Filed: Sep 21, 2018Published: Aug 29, 2019
Est. expiryOct 23, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 19/00A61P 19/08C12N 2533/54A61K 9/0019C12N 2506/03C12N 5/0605C12N 5/0654C12N 2500/38A61L 27/3847C12N 5/0668C12N 2501/39C12N 2500/42A61K 35/12C12N 2506/025C12N 2533/18A61L 27/3834A61K 47/42A61K 35/50A61K 47/36A61L 27/38C12N 5/0652A61F 2/28
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.

Claims

exact text as granted — not AI-modified
1 - 4 . (canceled) 
     
     
         5 . A method for treating bone defects in a subject, comprising administering to a subject in need thereof an implantable or injectable composition comprising a population of nonadherent stem cells, thereby treating the bone defect in the subject. 
     
     
         6 . The method of  claim 5 , wherein the bone defect is an osteolytic lesion associated with a cancer, a bone fracture, or a spine in need of fusion. 
     
     
         7 . The method of  claim 6 , wherein the osteolytic lesion is associated with multiple myeloma, bone cancer, or metastatic cancer. 
     
     
         8 . The method of  claim 6 , wherein the bone fracture is a non-union fracture. 
     
     
         9 . The method of  claim 5 , wherein the implantable composition is surgically implanted. 
     
     
         10 . The method of  claim 5 , wherein an injectable composition comprising a population of nonadherent stem cells is administered to the subject. 
     
     
         11 . The method of  claim 5 , wherein the injectable composition is surgically administered to the region of the bone defect. 
     
     
         12 . The method of  claim 5 , wherein the injectable composition is systemically administered. 
     
     
         13 - 14 . (canceled) 
     
     
         15 . A method for formulating an injectable composition, comprising combining a population of stem cells with injectable hyaluronic acid or collagen, wherein said stem cells are CD200+ or HLA-G+, or are CD34+ and CD44−. 
     
     
         16 . A method for treating bone defects in a subject, comprising administering to a subject in need thereof an implantable or injectable composition comprising a population of stem cells, wherein said stem cells are CD200+ or HLA-G+, or are CD34+ and CD44−, thereby treating the bone defect in the subject. 
     
     
         17 . The method of  claim 15 , wherein the bone defect is an osteolytic lesion associated with multiple myeloma, bone cancer, or metastic cancer, a bone fracture, or a spine in need of fusion. 
     
     
         18 . The method of  claim 15 , wherein an implantable composition comprising a population of nonadherent stem cells is administered to the subject. 
     
     
         19 . The method of  claim 17 , wherein the implantable composition is surgically implanted. 
     
     
         20 . The method of  claim 15 , wherein an injectable composition comprising a population of nonadherent stem cells is administered to the subject. 
     
     
         21 . The method of  claim 19 , wherein the injectable composition is systemically administered.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.